GO
Loading...

Pfizer Inc

More

  • LONDON, April 27- Britain's warning to potential suitors of BP is a sign of the oil major's vulnerability to a takeover bid and that a more politically palatable tie-up with Royal Dutch Shell no longer seems to be an option, banking and industry sources said. Despite championing a laissez-faire policy towards takeover deals, Britain has always had a special...

  • Early Glance: Pharmaceuticals companies Monday, 27 Apr 2015 | 11:25 AM ET

    Baxter International Inc. rose$. 15 or. 2 percent, to $71.29. Bristol-Myers Squibb Co. rose$. 16 or. 2 percent, to $65.96. Eli Lilly& Co. rose$. 09 or. 1 percent, to $71.67.

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...

  • NEW YORK— U.S. stocks rose slightly in morning trading Monday as investors looked ahead to a busy week for earnings news and a meeting by the Federal Reserve on interest rates. EYE ON EARNINGS: More than 150 companies in the S&P 500 are expected to report quarterly results this week, including Ford, Visa, Pfizer and Exxon Mobil. EYE ON APPLE: Apple rose $2.49, or 2 percent,...

  • Asian markets rise after Wall Street gains Sunday, 26 Apr 2015 | 11:42 PM ET

    BEIJING— Asian stock markets rose Monday after Wall Street gained on strong earnings and investors looked ahead to Apple results and this week's U.S. Sydney's S&P ASX 200 added 0.7 percent to 5,973.30 and Seoul advanced 0.2 percent to 2,163.17. Taiwan, Singapore and Manila also rose.

  • Final Glance: Pharmaceuticals companies Friday, 24 Apr 2015 | 8:08 PM ET

    Baxter International Inc. fell$. 37 or. 5 percent, to $71.14. Bristol-Myers Squibb Co. fell$. 20 or. 3 percent, to $65.80. Eli Lilly& Co. fell$. 82 or 1.1 percent, to $71.58.

  • NEW YORK, April 24- Healthcare companies on a seven-year tear have been top performers so far in 2015, helping to push broad stock indexes to record levels, but traders are now looking to protect themselves from a selloff as they await major earnings reports in the sector. Companies reporting first-quarter earnings next week include Bristol-Meyers Squibb Co,...

  • Midday Glance: Pharmaceuticals companies Friday, 24 Apr 2015 | 1:36 PM ET

    Baxter International Inc. fell$. 39 or. 5 percent, to $71.12. Bristol-Myers Squibb Co. fell$. 28 or. 4 percent, to $65.72. Eli Lilly& Co. fell$. 98 or 1.4 percent, to $71.42.

  • Most active New York Stock Exchange-traded stocks Friday, 24 Apr 2015 | 1:36 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:. AT&T Inc. rose. 1 percent to $34.27 with 24,327,600 shares traded. Bank of America Corp. fell. 3 percent to $15.65 with 22,512,500 shares traded.

  • Early Glance: Pharmaceuticals companies Friday, 24 Apr 2015 | 10:55 AM ET

    Baxter International Inc. fell$. 42 or. 6 percent, to $71.09. Bristol-Myers Squibb Co. fell$. 11 or. 2 percent, to $65.89. Pfizer fell$. 11 or. 3 percent, to $35.25.

  • Comcast's failed $45 billion deal for Time Warner Cable is a high-profile example of a failed deal, but it doesn't crack the list of the 10 largest. That distinction belongs to an unsolicited, $79.6 billion bid for Time Warner Inc. made by Rupert Murdoch's 21st Century Fox, according to financial data provider Dealogic. Time Warner Inc. spun off Time Warner Cable...

  • Stocks rise on tech earnings; Nasdaq adds to record Friday, 24 Apr 2015 | 4:43 AM ET

    NEW YORK— Stocks advanced slightly Friday as investors cheered the quarterly results of three large technology companies: Google, Microsoft and Amazon. Next week, more than 150 companies in the S&P 500 will report their results, including such market-moving names as Apple, Ford, Visa, Pfizer and Exxon Mobil. Microsoft, Amazon and Google all rose sharply after the...

  • AstraZeneca eyes new cancer deals after Nexium hit Friday, 24 Apr 2015 | 3:35 AM ET
    British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England.

    AstraZeneca has sharpened its focus on cancer drugs as it looks beyond a hit to sales from the launch of cheap copies of its acid pill Nexium.

  • LONDON, April 24- AstraZeneca has sharpened its focus on cancer drugs with two new deals as it looks beyond a hit to sales and profits from the launch of cheap copies of its popular stomach acid pill Nexium in the vital U.S. market. AstraZeneca will get an upfront payment of $450 million from Celgene, while Innate will receive an initial $250 million from...

  • Final Glance: Pharmaceuticals companies Thursday, 23 Apr 2015 | 6:05 PM ET

    Baxter International Inc. rose $1.13 or 1.6 percent, to $71.51. Bristol-Myers Squibb Co. fell$. 60 or. 9 percent, to $66.00. Eli Lilly& Co. rose$. 10 or. 1 percent, to $72.40.

  • Business events scheduled for the coming week Thursday, 23 Apr 2015 | 1:43 PM ET

    Restaurant Brands International Inc. reports quarterly financial results before the market opens. WASHINGTON— Standard& Poor's releases S&P/Case-Shiller index of home prices for February, 9 a.m.; The Conference Board releases the Consumer Confidence Index for April, 10 a.m.; Federal Reserve policymakers meet to set interest rates. WASHINGTON— Commerce...

  • Midday Glance: Pharmaceuticals companies Thursday, 23 Apr 2015 | 1:24 PM ET

    Baxter International Inc. rose $1.67 or 2.4 percent, to $72.05. Bristol-Myers Squibb Co. fell$. 54 or. 8 percent, to $66.06. Eli Lilly& Co. rose$. 25 or. 3 percent, to $72.55.

  • Early Glance: Pharmaceuticals companies Thursday, 23 Apr 2015 | 11:02 AM ET

    Baxter International Inc. rose $1.00 or 1.4 percent, to $71.38. Bristol-Myers Squibb Co. fell$. 63 or. 9 percent, to $65.97. Eli Lilly& Co. fell$. 98 or 1.4 percent, to $71.32.

  • April 23- A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells. The partnership between AstraZeneca's research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as...

  • April 23- Investment bank and asset manager Lazard Ltd reported a better-than-expected quarterly profit as a jump in corporate dealmaking boosted its M&A advisory fees. M&A and other advisory fees for Lazard, the sole adviser to H.J. Some of the other ongoing big deals that Lazard is part of include AT&T Inc's $67.1 billion bid for DirecTV and Pfizer Inc's $17...